Analysts Set $25.88 Price Target for OptimizeRx Co. (NASDAQ:OPRX)

Shares of OptimizeRx Co. (NASDAQ:OPRX) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus price target of $25.88 for the company and are anticipating that the company will post $0.08 EPS for the current quarter, according to Zacks. Zacks has also assigned OptimizeRx an industry rank of 102 out of 256 based on the ratings given to related companies.

Separately, Zacks Investment Research upgraded shares of OptimizeRx from a “hold” rating to a “strong-buy” rating and set a $16.00 price objective on the stock in a research note on Tuesday, May 14th.

OPRX stock opened at $16.20 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.02 and a quick ratio of 4.02. The company has a market capitalization of $181.55 million, a PE ratio of 324.00, a price-to-earnings-growth ratio of 1.70 and a beta of 0.52. OptimizeRx has a 1 year low of $8.92 and a 1 year high of $18.39. The company has a fifty day moving average of $14.74.

In related news, major shareholder Awm Investment Company, Inc. sold 82,126 shares of OptimizeRx stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $13.64, for a total transaction of $1,120,198.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Park West Asset Management LLC raised its stake in shares of OptimizeRx by 63.3% during the fourth quarter. Park West Asset Management LLC now owns 967,448 shares of the company’s stock valued at $10,613,000 after purchasing an additional 375,000 shares in the last quarter. 1492 Capital Management LLC acquired a new position in OptimizeRx during the fourth quarter worth about $1,454,000. Avenir Corp grew its holdings in OptimizeRx by 74.2% during the fourth quarter. Avenir Corp now owns 117,400 shares of the company’s stock worth $1,288,000 after acquiring an additional 50,000 shares during the period. Timpani Capital Management LLC grew its holdings in OptimizeRx by 51.5% during the fourth quarter. Timpani Capital Management LLC now owns 108,643 shares of the company’s stock worth $1,192,000 after acquiring an additional 36,949 shares during the period. Finally, Geode Capital Management LLC grew its holdings in OptimizeRx by 294.7% during the fourth quarter. Geode Capital Management LLC now owns 60,861 shares of the company’s stock worth $667,000 after acquiring an additional 45,440 shares during the period. Institutional investors and hedge funds own 48.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Read More: Why is total return important?

Get a free copy of the Zacks research report on OptimizeRx (OPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.